Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
3d agoen
From the article
Conditions : Seborrheic Dermatitis Interventions : Drug: Roflumilast Foam 0.3%; Drug: Vehicle foam Sponsors : Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Arcutis Biotherapeutics, Inc. Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
FDA approves bemotrizinol, first new sunscreen ingredient in over 25 years
The FDA has approved bemotrizinol, the first new sunscreen ingredient for the U.S. market in over 25 years. The ingredient, long used in Eur
apnews.com·25d ago
FDA approves bemotrizinol, first new sunscreen ingredient in nearly 30 years
The FDA has approved bemotrizinol, a new chemical UV filter for sunscreens, marking the first such approval in nearly 30 years. The ingredie
n.pr·25d ago
FDA approves bemotrizinol, first new sunscreen ingredient in over 25 years
The FDA has approved bemotrizinol, the first new sunscreen ingredient for the U.S. market in over 25 years. The ingredient, already used in
denverpost.com·29d ago
FDA Approves Bemotrizinol, First New Sunscreen Ingredient in Two Decades
The FDA has approved bemotrizinol, the first new sunscreen ingredient in the U.S. in 20 years. This broad-spectrum UV blocker has been used
time.com·29d ago
FDA approves bemotrizinol, first new sunscreen UV filter in nearly 30 years
The FDA has approved bemotrizinol, a new chemical UV filter for sunscreens, marking the first such approval in nearly 30 years. The ingredie
npr.org·25d ago以岭药业：厄贝沙坦化学原料药上市申请获批
36氪·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.